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Background: Transplantation biology has accumulated evidence of persistent mixed lymphohematopoietic
chimerism (MLHC) after allogeneic hematopoietic stem cell (HSC) grafting, resulting in donor-specific tolerance
to alloantigens in solid organ transplantation. We aimed to design a safe, non-toxic, non-myeloablative, high-
dose allogeneic HSC transplantation (HSCT) protocol to achieve grafting with persistent low-level MLHC-
associated, donor-specific tolerance across major histocompatibility complex barriers in our living related
donor (LRD) renal allograft recipients.
Methods: HSC infusion into the portal, marrow and systemic circulation was performed in 11 LRD renal
allograft recipients. All patients underwent a tolerance induction protocol (TIP), but two patients also had HSC
infusion (n = 1) or donor renal tissue inoculation (n = 1) into the recipient thymus. All patients received low-
dose immunosuppressive therapy for a mean of 1 year post-transplantation. Such therapy was discontinued for
the following reasons: poor compliance; drug toxicity; and low-level chimerism, as tested across gender-
mismatched donors by a fluorescent in situ hybridization technique.
Results: All patients had prope tolerance with early, stable allograft function without any episodes of rejection,
infection, or graft versus host disease. MLHC could be tested in seven patients, all of whom showed persistent
MLHC (average 0.54%) in peripheral blood. All patients had stable allograft function for a mean of 32.6
months after the withdrawal of immunosuppressive therapy, and all had a normal clinical profile as tested by
laboratory parameters.
Conclusion: Of 483 patients who underwent TIP using HSCT, weaning of immunosuppressive therapy was
implemented in 165 (34.2%), and 11 patients developed successful MLHC-associated donor-specific tolerance.
[Hong Kong J Nephrol 2005;7(1):27–33]
Key words: donor-specific transplantation tolerance, hematopoietic stem cell transplantation,
mixed lymphohematopoietic chimerism, renal transplantation, tolerance induction protocol
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INTRODUCTION
Clinical organ transplantation between major histo-
compatibility complex (MHC)-mismatched individ-
uals presently requires immunosuppressive agents to
prevent rejection. The use of such agents is associa-
ted with high morbidity and mortality, resulting from
various associated adverse effects, such as viral and
bacterial infections. In addition, such agents are not
always able to protect grafts from chronic rejection.
This situation requires the establishment of donor-
specific transplantation tolerance to eliminate the need
for long-term immunosuppressive therapy.
Since September 1998, we have used high-dose,
unmodified, allogeneic hematopoietic stem cell (HSC)
infusions to induce tolerance in patients undergoing
living related donor (LRD) renal transplantation. We
implemented a tolerance induction protocol (TIP), with
various conditioning modifications, in 483 patients,
all of whom achieved prope tolerance [1–4]. We report
11 patients from this group, in whom prolonged,
uneventful drug withdrawal was associated with the
successful development of donor-specific tolerance.
Our definition of allospecific tolerance is stable allograft
function, with normal biopsy and no immunosup-
pressive therapy for more than 100 days.
METHODS
Study protocol
Eleven patients with end-stage renal disease (ESRD)
underwent LRD renal transplantation across MHC
barriers. The 11 patients were retrospectively selected
from a population of 483 who underwent TIP, and for
whom studies were conducted in accordance with the
revised declaration of Helsinki; in addition, the
institutional ethics committee approved the study
protocols, and all patients gave informed consent to
participate. Demographic data for the 11 patients,
including donor-recipient human lymphocyte antigen
(HLA) match profile, are shown in Table 1.
All 11 patients received cytokine-stimulated and
mobilized donor-derived HSC infusion under different
protocols. The principal theme was to infuse high-dose
HSC in renal allograft recipients with an LRD and to
induce grafting, across MHC barriers, to lead to a very
low level of stable MLHC.
HSC stimulation, mobilization, collection and
infusion techniques
The LRDs of patients received granulocyte macrophage
colony stimulating factor 15 +g/kg body weight
subcutaneously for 4 consecutive days, followed by
leukophoresis on day 5 for donors whose recipients
were to be subjected to peripheral blood stem cell
(PBSC) infusion alone. Unmodified PBSCs procured
from donors were immediately infused into the peri-
pheral and/or portal circulation of recipients. This
procedure was repeated once or twice to reach the tar-
get of 15 = 108 cells/kg body weight in the recipients.
Cobe SpectraTM version 7 (Gambro China Ltd, Hong
Kong SAR, China) and Haemonetics® MCS® 3p
(Haemonetics Corp, Braintree, MA, USA) devices were
used for leukophoresis.
In some patients, stimulated bone marrow was
aspirated under local anesthesia and heavy sedation
from the posterior superior iliac crests as an adjuvant
to PBSC infusion. Nucleated and CD34+ cell counts
were performed after each collection.
HLA and lymphocytotoxicity cross-matching
(LCM) technique
All patients and donors were tested for HLA. LCM was
performed before and after TIP using conventional
serologic techniques (one-Lambda pre-dot trays were
used for typing HLA-A, -B, and -DR) and automatic
cross-match, dithiothreitol, and standard cytotoxicity
methods with mixed-cell populations. T- and B-
lymphocytes were used separately for cross-matching.
Renal transplantation was performed 1 week after the
last HSC infusion, after negative LCM.
Post-transplantation follow-up
All patients were followed at the same outpatient clinic
at weekly intervals for the first 3 months, fortnightly
for the next 3 months, at monthly intervals for the next
6 months, and at 3-monthly intervals thereafter. At each
visit, renal- and liver-function status was monitored,
complete blood counts were performed, and blood
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cyclosporine levels were measured using an enzyme-
multiplied immunoassay technique (EMIT) 2000
cyclosporine-specific assay system (Syva® Co, Dade
Behring Inc, Deerfield, IL, USA). Patients were
monitored at monthly intervals for the presence of
human immunodeficiency virus, hepatitis B surface
antigen, hepatitis C virus, and cytomegalovirus infec-
tion, using enzyme-linked immunosorbent assays. In
all patients, renal allograft biopsies were performed a
mean of 1 year after the withdrawal of immunosup-
pressive therapy.
Immunosuppression
Patients received cyclosporine 6 mg/kg/day and
prednisolone 0.5 mg/kg/day for the first 3 months.
Subsequently, the cyclosporine dosage was tapered to
3 mg/kg/day, and the prednisolone dosage to 0.2 mg/
kg/day. The cyclosporine dosage was adjusted to
maintain trough blood levels of 50–100 ng/mL (rec-
ommended trough values 76–150 ng/mL). Predni-
solone was discontinued 9 months after transplan-
tation.
Chimerism studies
Peripheral blood (5 mL in heparin) was collected from
seven patients in October 2003 and October 2004. Red
blood cells (RBCs) were lysed using RBC-lysis buffer
after spinning with phosphate-buffered saline at 4–10ºC
for 10 minutes. The lysed cells were spun in a Cytospin®
centrifuge (ALC Refrigerated Centrifuge Model PK
120R; Thermo Jouan, St Herblain Cedex, France), and
prepared slides were stained with Geimsa stain. The
slides were then de-stained and XX/XY (Vysis) probes
(Vysis Inc, Downers Grove, IL, USA) were applied.
The slides were then studied under a microscope for
chimerism (Skyvision Cytogenetics Workstation;
Applied Spectral Imaging, Carlsbad, CA, USA).
Case reports
Patient 1 (KD)
A 52-year-old woman underwent renal transplantation
with her 55-year-old husband’s kidney (0/6 HLA match)
on 28 September 1998; the patient had membranous
nephropathy leading to ESRD. PBSCs (10 = 108 cells/
kg; mean CD34+ count, 0.7%) were infused into the
patient’s peripheral circulation. Throughout the post-
transplant period, she maintained her baseline serum
creatinine (SCr) level of about 0.9 mg/dL. Three years
after transplantation, the patient stopped cyclosporine
on her own. At the time of writing, the patient’s SCr
level was 0.9 mg/dL and her peripheral blood MLHC
was 0.9%. She has a stable graft that has been
functioning without immunosuppressive therapy since
1 October 2001 (for approximately 2 years and 7
months).
Patient 2 (NP)
A 40-year-old woman underwent renal trans-
plantation with her 42-year-old husband’s kidney
(1/6 HLA match) on 6 October 1998; the patient had
chronic glomerulonephritis leading to ESRD. PBSCs
(11.8 = 108 cells/kg; mean CD34+ count, 0.7%) were
infused into the patient’s peripheral circulation.
Throughout the post-transplant period, she main-
tained her baseline SCr level of about 1.1 mg/dL. Three
years after transplantation, cyclosporine was stopped
because of hepatotoxicity (alanine aminotransferase,
2,500 IU/L; aspartate aminotransferase, 385 IU/L;
serum bilirubin, 1.2 mg/dL; negative viral markers).
The patient’s SCr level is now 1.32 mg/dL; she has a
normal liver function profile and her MLHC is
0.02%. She has a stable graft  that has been
functioning without immunosuppressive therapy
since 10 October 2001 (for approximately 2 years
and 7 months).
Table 1. Patient demographic data, including donor-recipient human lymphocyte antigen (HLA) mismatch profile
Patient Age HSC dose Immuno-
number (yr)/ Cause of ESRD Donor relationship, HLA mismatch (n = 108 Transplantation suppression
(initials) gender age (yr) cells/kg) date withdrawalA B DR date
1 (KD) 52/F Membranous nephropathy Husband, 55 2 2 2 10 28 Sep 1998 1 Oct 2001
2 (NP) 40/F Chronic glomerulonephritis Husband, 42 1 2 2 11.8 6 Oct 1998 10 Oct 2001
3 (DT) 22/M Chronic glomerulonephritis Mother, 42 1 1 1 16.4 10 May 1999 15 Apr 2000
4 (ID) 51/F Chronic interstitial nephritis Sister, 47 1 1 1 28.3 17 Aug 1999 10 Aug 2000
5 (RB) 42/M Diabetic nephropathy Cousin’s brother, 26 2 2 2 15.5 1 Sep 1999 1 Aug 2000
6 (JS) 28/M Chronic glomerulonephritis Brother, 30 1 2 1 19.7 4 Feb 2000 1 Feb 2001
7 (YS) 27/M Chronic glomerulonephritis Mother, 60 1 1 1 10.5 19 Feb 2001 1 Mar 2002
8 (BP) 20/M Obstructive uropathy Mother, 50 1 1 1 36.1 3 May 2001 1 Apr 2002
9 (DP) 30/M Renal tuberculosis Cousin’s sister, 31 2 2 1 24.1 14 Aug 2001 15 Jul 2002
10 (AS) 27/M Chronic glomerulonephritis Brother, 32 0 1 1 0.7 28 Sep 2001 1 Oct 2002
11 (AP) 36/M Reflux nephropathy Sister, 30 0 1 0 6.2 21 Aug 2002 15 Jul 2003
ESRD = end-stage renal disease; HSC = hematopoietic stem cell.
H.L. Trivedi, et al
30 Hong Kong J Nephrol • April 2005 • Vol 7 • No 1
Patient 3 (DT)
A 22-year-old man underwent renal transplantation
with his 42-year-old mother’s kidney (3/6 HLA
match) on 10 May 1999; the patient had chronic
glomerulonephritis leading to ESRD. He received an
infusion of donor bone marrow derived stem cells
(DBMC) in unmodified form (2.2 = 108 cells/kg;
mean CD34+ count, 1.0%) into the portal (250 mL)
and peripheral circulation (200 mL), followed by an
infusion of PBSCs (14.2 = 108 cells/kg; mean CD34+
count, 0.7%) peripherally. He maintained his
baseline SCr level of about 1.12 mg/dL. The
cyclosporine dosage was gradually reduced at 9
months post-transplant, and was stopped 3 months
later, with an uneventful follow-up and maintained
SCr level of 1.4 mg/dL. At present, the patient’s SCr
level is 1.39 mg/dL with MLHC of 0.05%. He has a
stable graft that has been functioning without
immunosuppressive therapy since 15 April 2000 (for
approximately 4 years and 1 month).
Patient 4 (ID)
A 51-year-old woman underwent renal transplantation
with her 47-year-old sister’s kidney (3/6 HLA match)
on 17 August 1999; the patient had chronic interstitial
nephritis leading to ESRD. PBSCs (28.3 = 108 cells/
kg; mean CD34+ count, 0.8%) were infused into the
patient’s portal and peripheral circulation. The patient
maintained her baseline SCr level of around 1.01
mg/dL. One year after transplantation, she stopped
immunosuppressive therapy on her own, and was lost
to follow-up, although she returned for a routine
checkup 2 years post-transplant, at which time her
SCr level was 1.2 mg%. The patient’s SCr level is
now 1.27 mg/dL and she had not received immuno-
suppressive therapy for approximately 3.8 years (since
10 August 2000).
Patient 5 (RB)
A 42-year-old man underwent renal transplantation
with a kidney from the 26-year-old brother of his
cousin (0/6 HLA match) on 1 September 1999; the
patient had diabetic nephropathy leading to ESRD.
PBSCs (15.5 = 108 cells/kg; mean CD34+ count,
0.8%) were infused into the patient’s portal and
peripheral circulation. He maintained his baseline
SCr level of around 0.9 mg/dL. One year after
transplantation, he stopped immunosuppressive
therapy on his own and was lost to follow-up,
although he returned for a routine checkup 2 years
post-transplant, at which time his SCr level was
0.9 mg/dL. The patient’s present SCr is 0.9 mg/dL,
and he had not received immunosuppressive ther-
apy for approximately 3.8 years (since 1 August
2000). The patient continues to be on insulin therapy
for his diabetes.
Patient 6 (JS)
A 28-year-old man underwent renal transplantation with
his 30-year-old brother’s kidney (2/6 HLA match) on
4 February 2000; the patient had chronic glomerulo-
nephritis leading to ESRD. PBSCs (19.7 = 108
cells/kg; mean CD34+ count, 0.8%) were infused
into the patient’s portal and peripheral circulation.
He maintained his baseline SCr level of around 1.1
mg/dL. The cyclosporine dosage was reduced over a
3-month period, and the patient had stopped
immunosuppressive therapy 1 year after transplan-
tation. The patient had an uneventful withdrawal of
immunosuppressive therapy and maintained his SCr
level of 1.1 mg/dL. His SCr level is currently 1.1 mg/dL,
and he had not received immunosuppressive ther-
apy for approximately 3.3 years (since 1 February
2001).
Patient 7 (YS)
A 27-year-old man underwent renal transplantation with
his 60-year-old mother’s kidney (3/6 HLA match) on
19 February 2001; the patient had chronic glomerulo-
nephritis leading to ESRD. PBSCs (10.5 = 108 cells/
kg; mean CD34+ count, 0.7%) were infused into the
patient’s portal and peripheral circulation. He main-
tained his baseline SCr level of around 1.05 mg/dL.
The cyclosporine dosage was reduced over a 3-month
period, and the patient had stopped immunosuppressive
therapy 1 year after transplantation. The patient had an
uneventful withdrawal of immunosuppressive therapy
and maintained an SCr level of 1.35 mg/dL. His present
SCr level is 1.5 mg/dL with MLHC of 0.7%, and he
had not received immunosuppressive therapy for
approximately 2.2 years (since 1 March 2002).
Patient 8 (BP)
A 20-year-old man underwent renal transplantation with
his 50-year-old mother’s kidney (3/6 HLA match) on 3
May 2001; the patient had obstructive uropathy leading
to ESRD. DBMCs in unmodified form (2.8 = 108 cells/
kg; mean CD34+ count, 1%) were injected into the
patient’s thymus (1.5 mL of concentrated inoculum),
marrow (60 mL), portal circulation (200 mL) and
peripheral circulation (140 mL). PBSCs (33.3 = 108
cells/kg; mean CD34+ count, 0.7%) were then infused
into the peripheral circulation. He maintained his
baseline SCr level of around 0.85 mg/dL. The cy-
closporine dosage was reduced over a 3-month peri-
od, and the patient had stopped immunosuppressive
therapy 1 year after transplantation. The patient had
an uneventful withdrawal of immunosuppres-
sive therapy and maintained an SCr level of 1.0 mg/
dL. At present, his SCr level is 1.0 mg/dL with
MLHC of 0.8%, and the patient had not received
immunosuppressive therapy for approximately 2.1
years (since 1 April 2002).
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Patient 9 (DP)
A 30-year-old man underwent renal transplantation with
a kidney from the 31-year-old sister of his cousin (1/6
HLA match) on 14 August 2001; the patient had renal
tuberculosis leading to ESRD. DBMCs in unmodified
form (1.9 = 108 cells/kg; mean CD34+ count, 1%) were
injected into the patient’s thymus (1.5 mL of concen-
trated inoculum), marrow (60 mL), portal circulation
(200 mL) and peripheral circulation (140 mL). PBSCs
(22.2 = 108 cells/kg; mean CD34+ count, 0.7%) were
then infused into the peripheral circulation. He main-
tained his baseline SCr level of around 0.79 mg/dL.
The cyclosporine dosage was reduced over a 3-
month period, and the patient had stopped immuno-
suppressive therapy 1 year after transplantation. The
patient had an uneventful withdrawal of immuno-
suppressive therapy and maintained an SCr level of
1.0 mg/dL. The patient’s SCr level is 1.0 mg/dL with
MLHC of 0.6% at present, and he had not been
receiving immunosuppressive therapy for approxi-
mately 1.9 years (since 15 July 2002).
Patient 10 (AS)
A 27-year-old man underwent renal transplantation with
his 32-year-old brother’s kidney (4/6 HLA match) on
28 September 2001; the patient had chronic glomeru-
lonephritis leading to ESRD. DBMCs in unmodi-
fied form (0.7 = 108 cells/kg; mean CD34+ count,
0.6%) were injected into the patient’s thymus (1.5 mL
of concentrated inoculum), marrow (80 mL), por-
tal circulation (200 mL) and peripheral circulation
(120 mL). He maintained his baseline SCr level of
around 0.79 mg/dL. The cyclosporine dosage was
reduced over a 3-month period, and the patient had
stopped immunosuppressive therapy 1 year after
transplantation. The patient had an uneventful
withdrawal of immunosuppressive therapy and main-
tained an SCr level of 1.0 mg/dL. At the time of writ-
ing, the patient’s SCr level was 0.9 mg/dL and he had
not received immunosuppressive therapy for approx-
imately 1.6 years (since 1 October 2002).
Patient 11 (AP)
A 36-year-old man underwent renal transplantation with
his 30-year-old sister’s kidney (5/6 HLA match) on 21
August 2002; the patient had reflux nephropathy
leading to ESRD. He received an injection of donor
renal tissue into his thymus. Renal tissue was procured
by a standard renal biopsy technique, under ultrasound
guidance, and inoculated into the thymus, which was
identified through a 10 cm incision made in the second,
left intercostal space under general anesthesia.
Subsequently, the patient received an infusion of
DBMCs in unmodified form (1.9 = 108 cells/kg; mean
CD34+ count, 0.9%) into marrow (60 mL), the portal
circulation (200 mL), and the peripheral circulation
(140 mL), and an infusion of PBMCs (4.3 = 108 cells/
kg; mean CD34+ count, 0.7%) into the peripheral
circulation. He maintained his baseline SCr level of
around 0.97 mg/dL. The cyclosporine dosage was
reduced over a 3-month period, and the patient had
stopped immunosuppressive therapy 1 year after
transplantation. The patient had an uneventful
withdrawal of immunosuppressive therapy and main-
tained an SCr level of 1.2 mg/dL. The patient’s
SCr level is now 1.2 mg/dL with MLHC of 0.7%, and
he had not received immunosuppressive therapy for
approximately 10 months (since 15 July 2003).
RESULTS
SCr levels
Over a mean follow-up period of 54.4 months, all the
patients had stable, adequate graft function, without any
rejection episodes or cytomegalovirus infection, and
with a mean SCr level of 1.13 mg/dL. Furthermore,
SCr levels remained largely unchanged for a mean of
38.6 months after the withdrawal of immunosuppressive
therapy. All patients had unremarkable allograft biop-
sies performed 115 ( 10 days after the complete with-
drawal of all immunosuppressive therapy.
MLHC analysis
Seven patients with grafts from the opposite sex were
analyzed for MLHC in peripheral blood in October
2003 and October 2004. Interestingly, as in previous
studies, persistent MLHC levels were identified (mean,
0.54%; Table 2). The Figure shows evidence of MLHC
in peripheral blood with the donor’s female cell showing
XX chromosomes amidst a male cell population with
XY chromosomes.
Besides the above seven patients who had stable
renal allografts for prolonged periods after stopping
immunosuppressive therapy, 165 patients from the
original cohort of 483 started an event-free, drug-
weaning protocol and are currently receiving low-dose
cyclosporine monotherapy.
DISCUSSION
Historically, in an experimental model of neonatal mice,
HSCT was used to create a permanent, robust tolerance
through mixed hematopoietic chimerism [5]; this was
the first ever demonstration of a link between mixed
chimerism and tolerance. Furthermore, donor-specific
tolerance was induced in a miniature swine model using
myeloablative conditioning and donor bone marrow
transplantation (BMT) [6,7], and in cynomolgus mon-
keys, the presence of transient, peripheral chimer-
ism was sufficient to induce permanent allospecific
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tolerance to renal allografts [8,9]. Thus, the use of do-
nor lymphohematopoietic cells as the key therapeu-
tic maneuver to achieve stable, drug-free, antigen-
dependent, T cell exhaustion and chimerism has been
envisioned for use clinically [10]. It is, therefore, logical
to infer that chimerism is a strong predictor of
successful tolerance induction. Microchimerism has
been reported in patients receiving large doses of
cadaveric BMT in conjunction with solid organ
transplantation and standard immunosuppressive
therapy [11–14]. The level of microchimerism declined
continuously during the first year after transplanta-
tion, and these patients continued to receive standard
immunosuppressive therapy.
Immune tolerance to renal allografts was reported
after BMT from an HLA-identical donor in patients
with acute leukemia and multiple myeloma [15,16].
We designed and implemented a protocol in an adult
human model to validate the Medawarian concept
of chimerism-related tolerance, based principally on
non-myeloablative, high-dose DBMC infusions into
the portal and peripheral circulation without any
conditioning [1–4]. Our data demonstrate appropriate
tolerance induction with this protocol, and findings
for the abovementioned 11 patients helped us to
identify donor-specific tolerance. However, no
laboratory test is available to allow us to decide the
optimum time for withdrawal of immunosuppressive
therapy.
In summary, this is the first report of successful
induction of very low level, stable MLHC-associated,
allospecific, immune tolerance in renal transplantation
(across MHC barriers) using high-dose, allogeneic
HSCs. Of 483 patients who underwent TIP using HSCT,
weaning of immunosuppressive therapy has been
implemented in 165 (34.2%), and 11 patients have
developed successful MLHC-associated donor-specific
tolerance. In addition, TIP was safe and no adverse
effects were reported.
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